Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma

Nature Medicine, Published online: 06 October 2026; doi:10.1038/s41591-026-04704-z Extended follow-up of four patients with multiple myeloma treated with in vivo BCMA CAR-T cells showed limited duration of response in three patients, while one patient had sustained response to 15 months.

We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.

Read the original at nature.com →

More in Health & Medicine

More from Tuesday 6 October →